Hydrochlorothiazide 25 mg daily is the preferred choice over chlorthalidone 25 mg daily for most patients with hypertension.
Despite older guideline recommendations favoring chlorthalidone, the most recent high-quality evidence from the 2022 Diuretic Comparison Project (DCP) trial—the only head-to-head randomized controlled trial—found no cardiovascular benefit with chlorthalidone compared to hydrochlorothiazide, while chlorthalidone caused significantly more hypokalemia 1.
Key Evidence from the DCP Trial
The 2022 DCP trial randomized 13,523 veterans (mean age 72 years) already taking HCTZ 25-50 mg to either continue HCTZ or switch to chlorthalidone 12.5-25 mg 1. After 2.4 years:
- No difference in major cardiovascular events: 10.4% with chlorthalidone vs 10.0% with HCTZ (HR 1.04,95% CI 0.94-1.16)
- Significantly more hypokalemia with chlorthalidone: 6.0% vs 4.4% (P<0.001)
- No differences in MI, stroke, heart failure, or non-cancer deaths
The 2026 per-protocol analysis of this same trial actually suggested a trend toward worse outcomes with chlorthalidone (5-year risk ratio 1.36,95% CI 0.96-2.12), though not statistically significant 2.
Why Guidelines Previously Favored Chlorthalidone
The 2017 ACC/AHA guidelines state "chlorthalidone is preferred on the basis of prolonged half-life and proven trial reduction of CVD" 3, 4. However, this recommendation was based on:
- Indirect comparisons from older trials (ALLHAT used chlorthalidone; other trials used HCTZ)
- No direct head-to-head trials existed at that time
- Pharmacologic assumptions about longer half-life translating to better outcomes
The 2025 ACC/AHA guideline now acknowledges that "replacing thiazide-type diuretics (eg, HCTZ) with thiazide-like diuretics (eg, chlorthalidone) may offer additional BP reduction" but notes this is primarily relevant in resistant hypertension contexts 5.
Safety Profile Comparison
Multiple large observational studies consistently show chlorthalidone carries greater risks:
- Hypokalemia risk 2.7-3.1 times higher with chlorthalidone 6, 7, 8
- Higher rates of hyponatremia (HR 1.31-1.68) 7, 8
- Increased acute kidney injury (HR 1.37) and chronic kidney disease (HR 1.24) 7
- More eGFR decline ≥30% (HR 1.24) 9
The 2021 Canadian study found chlorthalidone associated with higher cardiovascular events (HR 1.12) and more hypokalemia, particularly in patients with better kidney function 9.
Clinical Algorithm for Diuretic Selection
Start with HCTZ 25 mg daily for:
- Initial hypertension treatment
- Elderly patients (higher hypokalemia risk)
- Patients with eGFR <45 mL/min/1.73 m² (electrolyte risks)
- Patients on ACE inhibitors/ARBs (additive hyperkalemia risk makes HCTZ's lower potassium-wasting effect safer)
Consider chlorthalidone 12.5-25 mg daily only for:
- Resistant hypertension requiring 4+ medications (where the 2025 guidelines specifically recommend thiazide-like diuretics as part of the regimen) 5
- Prior MI or stroke: The 2024 DCP subgroup analysis showed chlorthalidone reduced events in this specific population (HR 0.73,95% CI 0.57-0.94) 10
Important Caveats
Monitor electrolytes closely if using chlorthalidone:
- Check potassium and sodium at 2-4 weeks after initiation
- Recheck with any dose increase
- More frequent monitoring in elderly, CKD patients, or those on ACE inhibitors/ARBs
Dose equivalency matters: Chlorthalidone 12.5 mg ≈ HCTZ 25 mg in potency 6. The higher potency explains both the similar BP effects and increased adverse effects.
The "proven in trials" argument is outdated: While ALLHAT used chlorthalidone, the DCP trial directly tested whether this translates to superiority—it does not for general hypertension 1.
Bottom Line
For routine hypertension management, HCTZ 25 mg daily is preferred over chlorthalidone 25 mg due to equivalent cardiovascular protection with significantly better safety profile 1. Reserve chlorthalidone for resistant hypertension or patients with prior MI/stroke where specific evidence supports its use 5, 10.